Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06799013 · ClinicalTrials.gov registry record · Phase 1
Safety and Immunogenicity of a Self-Amplifying RNA Vaccine Against Crimean-Congo Hemorrhagic Fever
A Phase 1 study of Vaccine and Crimean-Congo Hemorrhagic Fever, sponsored by HDT Bio.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT06799013 is a Phase 1 study of Vaccine and Crimean-Congo Hemorrhagic Fever that is actively recruiting participants, run by HDT Bio. The registered enrollment target is 48 participants, below the 13,297-participant average among 6 other Vaccine trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06799013, a Phase 1 study of Vaccine and Crimean-Congo Hemorrhagic Fever, is actively recruiting participants, sponsored by HDT Bio.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to assess the safety, tolerability and immunogenicity of three dosage levels, and a single or two-dose administration regimen, of the investigational HDT-321 product administered intra-muscularly. The main questions it aims to answer are: * Is HDT-321 safe to use * Does HDT-321 provide protection against Crimean-Congo hemorrhagic fever virus (CCHFV) Researchers will record any adverse events and test blood samples to see if HDT-321 is safe and works to protect participants against Crimean-Congo hemorrhagic fever virus (CCHFV) Participants will: * Receive 1 or 2 doses of HDT-321 * Complete a memory aid and measurements for 7 days after receiving each dose of HDT-321 * Be followed throughout the study using phone calls and clinic visits to check for and record adverse events * Provide blood samples at specific study visits
Conditions Studied
Interventions
- BIOLOGICAL 10 ug HDT 321
- BIOLOGICAL 25ug HDT-321
- BIOLOGICAL 50ug HDT-321
Study Locations (1)
Texas
- Flourish Research San Antonio (Clinical Trials of Texas) - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2025-07-10 |
| Est. Completion | 2027-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06799013
The ClinicalTrials.gov registry entry for NCT06799013 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 13,297-participant average among 6 other Vaccine trials with a reported enrollment target (100% lower). The listed sponsor is HDT Bio, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Vaccine appearing as the primary indexed condition, and to 3 interventions - of which 10 ug HDT 321 is the first listed.
NCT06799013 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06799013 about?
NCT06799013 is a clinical study titled "Safety and Immunogenicity of a Self-Amplifying RNA Vaccine Against Crimean-Congo Hemorrhagic Fever". The goal of this clinical trial is to assess the safety, tolerability and immunogenicity of three dosage levels, and a single or two-dose administration regimen, of the investigational HDT-321 product administered intra-muscularly. The main questions it aims to answer are: * Is HDT-321 safe to use ...
What is the current status of trial NCT06799013?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2025-07-10. Estimated completion is 2027-07.
What conditions does trial NCT06799013 study?
This clinical trial studies the following conditions: Vaccine, Crimean-Congo Hemorrhagic Fever.
What interventions are being tested in trial NCT06799013?
The interventions under investigation include: 10 ug HDT 321 (BIOLOGICAL), 25ug HDT-321 (BIOLOGICAL), 50ug HDT-321 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06799013?
This trial is sponsored by HDT Bio, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06799013 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Vaccine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Connecting Friends and Health Workers to Boost COVID-19 Vaccination in Latino Communities
RECRUITING · NA
-
Induction of Gut Permeability by an Oral Vaccine
ACTIVE NOT RECRUITING · Early Phase 1
-
PFAS Exposure and Immune Response to Vaccination in Adults
COMPLETED · Phase 4
-
Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-Based Anti-Cytomegalovirus (CMV) Vaccine (Triplex®)
COMPLETED · Phase 2
-
State Immunization Information Systems to Improve HPV Vaccination Rates
COMPLETED · NA
-
HPV Message Testing and Social Media Campaign
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.